A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1/2
385
about 6.4 years
18+
14 sites in CA, CO, IA +8
About this study
This trial is testing a treatment called JNJ-90014496 for people with relapsed or refractory B-cell non-Hodgkin lymphoma. The treatment is an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy targeting both CD19 and CD20.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive JNJ-90014496
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Phase 1b: Occurrence of Adverse Events (AEs) [Safety and Tolerability], Phase 2: Overall Response (OR) As Assessed by Independent Review Committee (IRC)
Secondary: Change From Baseline of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Symptom Score, Phase 1b: Duration of Response (DOR), Phase 1b: Overall Response (OR), Phase 1b: Pharmacokinetic Evaluation of Prizlo-Cel, Phase 2: Area Under the Blood Concentration Time Curve (AUC) for Prizlo-Cel, Phase 2: Complete Response (CR), Phase 2: Duration of Response (DOR), Phase 2: Maximum Observed Blood Concentration (Cmax) for Prizlo-Cel
Oncology